These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29978679)

  • 1. Biosimilars: The Challenges of Novelty, Inventive Step and Sufficiency.
    Henriksen T; Sanderson J
    J Law Med; 2018 Jul; 25(4):973-991. PubMed ID: 29978679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are pharmaceutical patent term extensions justified? Australia's evolving scheme.
    Lawson C
    J Law Med; 2013 Dec; 21(2):379-98. PubMed ID: 24597388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Freedom of information applications as an "evergreening" tactic: Secretary, Department of Health and Ageing v iNOVA Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442.
    Vines T; Faunce T
    J Law Med; 2011 Sep; 19(1):43-52. PubMed ID: 21988009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Are Biosimilars Not Living up to Their Promise in the US?
    Zhai MZ; Sarpatwari A; Kesselheim AS
    AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-based Process Development of Biosimilars as Part of the Quality by Design Paradigm.
    Zalai D; Dietzsch C; Herwig C
    PDA J Pharm Sci Technol; 2013; 67(6):569-80. PubMed ID: 24265299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocratic obligation to shareholder profit? Medical treatment patents and the Australian High Court in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50.
    Vines T
    J Law Med; 2014 Jun; 21(4):797-809. PubMed ID: 25087362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White paper: an outlook on U.S. biosimilar competition.
    Bourgoin AF; Nuskey B
    Drugs Today (Barc); 2013 Jun; 49(6):399-410. PubMed ID: 23807943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New forms of evergreening in Australia: misleading advertising, enantiomers and data exclusivity: Apotex v Servier and Alphapharm v Lundbeck.
    Faunce T; Vines T; Gibbons H
    J Law Med; 2008 Oct; 16(2):220-32. PubMed ID: 19010001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Sufficiency" for living organism inventions under the Patents Act 1990 (Cth).
    Lawson C
    J Law Med; 2004 Feb; 11(3):373-81. PubMed ID: 15018213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
    Carver KH; Elikan J; Lietzan E
    Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Similar but not identical biosimilars: the vision of innovators].
    Sydow S; Grajer KH
    Pharm Unserer Zeit; 2012 Nov; 41(6):474-80. PubMed ID: 23362551
    [No Abstract]   [Full Text] [Related]  

  • 20. Patent litigation could make 2017 no 'dancing' matter.
    Reinke T
    Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.